Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death.

ABSTRACT: Death receptors (DR4 and DR5) offer attractive targets for cancer treatment because cancer cell death can be induced by apoptotic signal upon binding of death ligands such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with death receptors. Cyclometalated iridium(III) complexes such as fac-Ir(tpy)₃ (tpy = 2-(4-tolyl)pyridine) possess a C₃-symmetric structure like TRAIL and exhibit excellent luminescence properties. Therefore, cyclometalated Ir complexes functionalized with DR-binding peptide motifs would be potent TRAIL mimics to detect cancer cells and induce their cell death. In this study, we report on the design and synthesis of C₃-symmetric and luminescent Ir complex-peptide hybrids (IPHs), which possess cyclic

SUBMITTER: Masum AA 

PROVIDER: S-EPMC6092981 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature